The total return over the past 12 months is -67.14% vs. +16.94% for the S&P 500. So far it's up -53.94% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (67.16%) | +2.88% | (46.33%) | (44.61%) | (47.37%) | (50.26%) |
| Total Return CAGR | (67.14%) | +2.88% | (46.33%) | (44.60%) | (47.37%) | (50.26%) |
| Revenue CAGR | (303.44%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ABVC BioPharma, Inc. (ABVC)
| Year | Start price | End price | ABVC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.13 | $0.98 | (53.94%) | +14.51% | (68.45%) |
| 2025 | $0.59 | $2.13 | +260.49% | +17.72% | +242.77% |
| 2024 | $1.16 | $0.59 | (49.06%) | +24.89% | (73.95%) |
| 2023 | $6.25 | $1.16 | (81.46%) | +26.19% | (107.65%) |
| 2022 | $33.90 | $6.25 | (81.56%) | (18.17%) | (63.39%) |
| 2021 | $51.00 | $33.90 | (33.53%) | +28.74% | (62.27%) |
| 2020 | $43.70 | $51.00 | +16.70% | +18.37% | (1.67%) |
| 2019 | $360.00 | $43.70 | (87.86%) | +31.22% | (119.08%) |
| 2018 | $360.00 | $360.00 | 0.00% | (4.56%) | +4.56% |
| 2017 | $360.00 | $360.00 | 0.00% | +21.70% | (21.70%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
